Literature DB >> 8216266

Establishment of radioimmunoassay for human neutrophil peptides and their increases in plasma and neutrophil in infection.

K Shiomi1, M Nakazato, T Ihi, K Kangawa, H Matsuo, S Matsukura.   

Abstract

Neutrophil peptide, also called defensin, is an antimicrobial peptide localized in azurophil granules in neutrophils. Using a synthetic human neutrophil peptide-1 (HNP-1), we prepared an antiserum against the peptide and established a highly sensitive radioimmunoassay (RIA). This RIA equally recognized HNP-1, -2, and -3 on a molar basis. Analyses of leukocyte and blood extracts obtained from normal individuals and patients with bacterial infection by reverse-phase high-performance liquid chromatography coupled with the RIA showed that the antiserum specifically detected HNP molecules. Concentrations of HNP 1-3 in total in normal human blood and plasma are 13.2 +/- 1.4 (mean +/- SEM) ng/mu 1 and 403.8 +/- 38.9 pg/mu 1, respectively. The values increased in infection and returned to within the normal levels after the recovery of the disorder. Granulocyte colony-stimulating factor (G-CSF) increased the plasma and blood concentrations of HNP 1-3. The RIA established here provides a useful tool to elucidate the pathophysiological significance of HNP and to evaluate the neutrophil functions in infection and inflammation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8216266     DOI: 10.1006/bbrc.1993.2190

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

1.  Dynamic changes in neutrophil defensins during endotoxemia.

Authors:  M E Klut; B A Whalen; J C Hogg
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

2.  Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity.

Authors:  Theresa L Chang; Jesus Vargas; Armando DelPortillo; Mary E Klotman
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

3.  Defensins and other antimicrobial peptides at the ocular surface.

Authors:  Alison M McDermott
Journal:  Ocul Surf       Date:  2004-10       Impact factor: 5.033

4.  Suppression of hepatic glucose production by human neutrophil alpha-defensins through a signaling pathway distinct from insulin.

Authors:  Hui-Yu Liu; Qu Fan Collins; Fatiha Moukdar; Degen Zhuo; Jianmin Han; Tao Hong; Sheila Collins; Wenhong Cao
Journal:  J Biol Chem       Date:  2008-03-17       Impact factor: 5.157

5.  Cyclic and acyclic defensins inhibit human immunodeficiency virus type-1 replication by different mechanisms.

Authors:  Aprille Seidel; Ying Ye; Lesley R de Armas; Maira Soto; William Yarosh; Renee A Marcsisin; Dat Tran; Michael E Selsted; David Camerini
Journal:  PLoS One       Date:  2010-03-17       Impact factor: 3.240

6.  Human alpha-defensins inhibit BK virus infection by aggregating virions and blocking binding to host cells.

Authors:  Aisling S Dugan; Melissa S Maginnis; Joslynn A Jordan; Megan L Gasparovic; Kate Manley; Rebecca Page; Geoffrey Williams; Edith Porter; Bethany A O'Hara; Walter J Atwood
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

Review 7.  Alarmins link neutrophils and dendritic cells.

Authors:  De Yang; Gonzalo de la Rosa; Poonam Tewary; Joost J Oppenheim
Journal:  Trends Immunol       Date:  2009-08-21       Impact factor: 16.687

8.  Localization of human neutrophil peptide (HNP) and its messenger RNA in neutrophil series.

Authors:  Y Date; M Nakazato; K Shiomi; H Toshimori; K Kangawa; H Matsuo; S Matsukura
Journal:  Ann Hematol       Date:  1994-08       Impact factor: 3.673

9.  Raised plasma concentrations of alpha-defensins in patients with idiopathic pulmonary fibrosis.

Authors:  H Mukae; H Iiboshi; M Nakazato; T Hiratsuka; M Tokojima; K Abe; J Ashitani; J Kadota; S Matsukura; S Kohno
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

10.  Salivary antimicrobial peptides (LL-37 and alpha-defensins HNP1-3), antimicrobial and IgA responses to prolonged exercise.

Authors:  Glen Davison; Judith Allgrove; Michael Gleeson
Journal:  Eur J Appl Physiol       Date:  2009-03-05       Impact factor: 3.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.